Trade

with

Apricus Biosciences Inc
(NASDAQ: APRI)
AdChoices
1.56
-0.08
-4.88%
After Hours :
1.55
-0.01
-0.63%

Open

1.72

Previous Close

1.64

Volume (Avg)

115.28k (150.52k)

Day's Range

1.52-1.72

52Wk Range

1.12-2.71

Market Cap.

62.49M

Dividend Rate ( Yield )

-

Beta

2.42

Shares Outstanding

38.10M

P/E Ratio (EPS)

-

AdChoices
Fundamentals
  • Key statistics
  • Growth
  • Profitability
  • Financial health
  • Price ratios
  • Trading statistics
Industry Drug Manufacturers – Specific & Generic
Highlights
Analyst Recommendation: Buy
    • Revenue

    • 2.51M

    • Net Income

    • -16.94M

    • Market Cap.

    • 62.49M

    • Enterprise Value

    • -

    • Net Profit Margin %

    • -97.79

    • PEG (Price/Earnings Growth) Ratio

    • -

    • Beta

    • 2.42

    • Forward P/E

    • -6.19

    • Price/Sales

    • 10.55

    • Price/Book Value

    • 5.27

    • Price/Cash flow

    • -7.33

      • EBITDA

      • -17.29M

      • Return on Capital %

      • -24.21

      • Return on Equity %

      • -45.29

      • Return on Assets %

      • -24.21

      • Book Value/Share

      • 0.31

      • Shares Outstanding

      • 38.10M

      • Last Split Factor (Date)

      • -

      • Last Dividend (Ex-Date)

      • -

      • Dividend Declaration Date

      • -

      Analyst Recommendation
      10/17/2014
      Buy
        • 1 Year Price Target

        • 4.17

        • Credit Rating

        • -

        • Analysts

        • 3

        • EPS Estimate

        • -

        • Cashflow Estimate

        • -

        Morningstar Consensus estimate data
        • Growth Rate (%)

        • Company

        • Industry

          • Sales (Revenue)

            Q/Q (last year)

          • 357.60

          • 7.67

          • Net Income

            YTD/YTD (last year)

          • -

          • -26.33

          • Net Income

            Q/Q (last year)

          • -

          • 197.54

          • Sales (Revenue)

            5-Year Annual Average

          • -15.87

          • -5.42

          • Net Income

            5-Year Annual Average

          • -

          • 3.16

          • Dividends

            5-Year Annual Average

          • -

          • -0.13

          • Profit Margins (%)

          • Company

          • Industry

            • Gross Margin

            • 97.38

            • 64.72

            • Pre-Tax Margin

            • -117.92

            • 13.77

            • Net Profit Margin

            • -97.79

            • 10.84

            • Average Gross Margin

              5-Year Annual Average

            • 40.60

            • 67.80

            • Average Pre-Tax Margin

              5-Year Annual Average

            • -611.40

            • 15.58

            • Average Net Profit Margin

              5-Year Annual Average

            • -633.00

            • 343.47B

            • Financial Ratios

            • Company

            • Industry

              • Debt/Equity Ratio

              • -

              • 0.33

              • Current Ratio

              • 2.70

              • 1.52

              • Quick Ratio

              • 2.51

              • 0.87

              • Interest Coverage

              • -

              • 6.77

              • Leverage Ratio

              • 1.71

              • 1.91

              • Book Value/Share

              • 0.31

              • 16.21

              • Price Ratios

              • Company

              • Industry

                • Current P/E Ratio

                • -8.95

                • 63.29

                • P/E Ratio 5-Year High

                • -68.66

                • 237.47

                • P/E Ratio 5-Year Low

                • -6.11

                • 19.71

                • Price/Sales Ratio

                • 10.55

                • 3.53

                • Price/Book Value

                • 5.27

                • 3.31

                • Price/Cash Flow Ratio

                • -7.33

                • 21.23

                • Key Metrics

                • Company

                • Industry

                  • Return on Equity %

                    (5-Year Average)

                  • -45.29

                    (-579.00)

                  • 7.86

                    (9.58)

                  • Return on Assets %

                    (5-Year Average)

                  • -24.21

                    (-139.30)

                  • 4.14

                    (5.54)

                  • Return on Capital %

                    (5-Year Average)

                  • -41.07

                    (-237.80)

                  • 5.59

                    (7.66)

                  • Income/Employee

                  • -

                  • 27.79k

                  • Inventory Turnover

                  • 0.47

                  • 1.80

                  • Asset Turnover

                  • 0.25

                  • 0.38

                  Current Historical
                  Financials
                  • Income Statement
                  • Balance Sheet
                  • Cash Flow
                  Operating Income
                  -17.37M
                  Operating Margin
                  -691.64
                  Total Equity
                  -
                  Retained Earnings
                  -
                  Free Cashflow
                  -
                  Price/Cashflow
                  -7.33
                  Ownership

                  Institutional Ownership

                  8.35%

                  Top 10 Institutions

                  7.76%

                  Mutual Fund Ownership

                  4.06%

                  Float

                  99.18%

                  5% / Insider Ownership

                  31.26%

                  Corporate insiders or major stockholders reporting trading activity in the stock.

                  Top Mutual Fund Owners

                  Top Institutional Owners

                  Mutual Fund Name

                  Institution Name

                  • Mutual Fund Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Total Stock Mkt Idx

                  •  

                    654,162

                  • 0.00

                  • 1.72

                  • Vanguard Extended Market Index Fund

                  •  

                    335,016

                  • 2.37

                  • 0.88

                  • Vanguard Instl Total Stock Market Index

                  •  

                    120,161

                  • 0.00

                  • 0.32

                  • iShares Micro-Cap

                  •  

                    115,196

                  • 0.00

                  • 0.33

                  • Fidelity Spartan® Extended Mkt Indx Fd

                  •  

                    103,681

                  • 0.00

                  • 0.27

                  • Symphonia Azionario USA

                  •  

                    36,113

                  • 0.00

                  • 0.09

                  • Vanguard Balanced Index Fund

                  •  

                    31,988

                  • 0.00

                  • 0.08

                  • Fidelity Spartan® Total Market Idx Fund

                  •  

                    18,211

                  • 0.00

                  • 0.05

                  • STAAR Smaller Company Stock Fund

                  •  

                    15,500

                  • 19.23

                  • 0.04

                  • Institution Name

                  • Shares Held

                  • % Change

                  • % Outstanding

                  • Vanguard Group, Inc.

                  •  

                    1,121,465

                  • 0.00%

                  • 2.94

                  • Visium Asset Management LLC

                  •  

                    1,102,000

                  • 0.00%

                  • 2.89

                  • California Public Employees Retrmnt Sys

                  •  

                    258,130

                  • 0.00%

                  • 0.68

                  • Geode Capital Management, LLC

                  •  

                    126,400

                  • -0.07%

                  • 0.33

                  • BlackRock Fund Advisors

                  •  

                    123,560

                  • +2.94%

                  • 0.32

                  • Northern Trust Investments, N.A.

                  •  

                    63,256

                  • -2.31%

                  • 0.17

                  • BNY Mellon Asset Management Ltd.

                  •  

                    50,232

                  • +1.43%

                  • 0.13

                  • Symphonia SGR S.p.A.

                  •  

                    36,113

                  • 0.00%

                  • 0.09

                  Company Profile

                  Sector

                  Healthcare

                  Industry

                  Drug Manufacturers – Specific & Generic

                  Type

                  Distressed

                  Style

                  Small Core

                  Apricus Biosciences, Inc., was incorporated in Nevada in 1987. It is a pharmaceutical company, that develops and commercializes pharmaceutical products that treat large patient populations with operations based in the United States. ...moreIts products have been developed utilizing its NexACT proprietary permeation enhancement technology. Its initial approved product is Vitaros approved in Canada for the treatment of erectile dysfunction (ED) and its next in-line late stage product candidate is Femprox for the treatment of female sexual arousal disorder (FSAD). It has also filed for approval of Vitaros for the treatment of ED in Europe through the Decentralized Approval Process (DCP) and in Switzerland. Femprox has completed one Phase III clinical trial in China and the Company is developing a regulatory s...moreubmission plan for additional clinical trials in the U.S., Canada and Europe. The Company operates in a single segment, through which it design and develop pharmaceutical products with our NexACT platform. On December 14, 2009, the Company acquired Bio-Quant, Inc. (Bio-Quant), a specialty biotech contract research organization (CRO) based in San Diego, California. It own an approximate total of 83 registered trademarks as well as 65 pending trademark applications and 5 allowed pending trademark applications worldwide. It owns registered trademarks for Vitaros, Femprox and NexACT in certain countries and territories.lessless

                  Key People

                  Richard W. Pascoe

                  CEO/Director

                  Dr. Kleanthis G. Xanthopoulos,PhD

                  Chairman of the Board/Director

                  Steven Martin

                  CFO/Chief Accounting Officer/Senior VP/Secretary

                  Mr. Edward Cox

                  Vice President, Divisional

                  Dr. Wendell D. Wierenga,PhD

                  Director

                  • Apricus Biosciences Inc

                  • 11975 El Camino Real

                  • San Diego, CA 92130

                  • USA.Map

                  • Phone: +1 858 222-8041

                  • Fax: +1 858 436-8155

                  • apricusbio.com

                  Incorporated

                  1987

                  Employees

                  21

                  Send Feedback

                  We appreciate your input!

                  • I'm having trouble signing into my Microsoft account

                  • I’m having problems with the services stripe (Mail, Facebook, etc.)

                  • There is an issue with my weather information

                  • I see an error in the content

                  • Other

                  Please give an overall site rating: